Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan.

ABSTRACT: The clinical syndrome of heart failure (HF) can be described as the reduced capacity of the heart to deliver blood throughout the body. To compensate for inadequate tissue perfusion, the renin-angiotensin aldosterone system (RAAS) and the sympathetic nervous system (SNS) become activated, resulting in increased blood pressure, heart rate, and blood volume. Consequent activation of the natriuretic peptide system (NPS) typically balances these effects; however, the NPS is unable to sustain compensation for excessive neurohormonal activation over time. Until recently, mortality benefits have been provided to patients with HF only by therapies that target the RAAS and SNS, including angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), mineralocorticoid recept

SUBMITTER: Liu RC 

PROVIDER: S-EPMC6267534 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature